Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of hodgkin's lymphoma? not any more

Ivan Netuka, Pavla Stepankova, Marian Urban, Jiri Maly, Ondrej Szarszoi, Zora Dorazilova, Tomas Kotulak, Jan Pirk

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hodgkin's lymphoma is a quite frequent diagnosis, particularly in younger patients, which is normally treated effectively with combined chemotherapy and radiotherapy. Cardiomyopathy induced by these treatments is not uncommon and may progress to advanced-stage heart failure. Due to the cardiotoxicity of chemotherapy for Hodgkin's disease, preexisting heart failure precludes usual therapy. We present a novel strategy of hemodynamic stabilization with an implantable left ventricular assist device (LVAD) prior to radical oncotherapy for Hodgkin's lymphoma. A 33-year-old man with a short history of progressive heart failure was hospitalized due to progressive symptoms. An echocardiogram revealed a dilated left ventricle with an ejection fraction of 18%, moderate right ventricular dysfunction, and moderate to severe tricuspid regurgitation. Supradiaphragmatic-stage Hodgkin's lymphoma was also diagnosed. Due to severe cardiac dysfunction, the patient was not a candidate for the usual chemotherapy and radiotherapy prescribed for this diagnosis. After multidisciplinary consultation and consent from the patient, an LVAD was implanted with tricuspid valve repair. Additionally, affected lymph nodes from the ventral upper mediastinum were excised, and pathological analysis confirmed the lymphoma diagnosis. The patient recovered from surgery and the postoperative course was uneventful. With LVAD support and normalized hemodynamics, chemotherapy and radiotherapy for his Hodgkin's lymphoma were completed, and the patient remains in complete remission documented by positron emission tomography/computed tomography and is well one since LVAD implantation.

Original languageEnglish (US)
Pages (from-to)320-321
Number of pages2
JournalASAIO Journal
Volume59
Issue number3
DOIs
StatePublished - May 1 2013

Fingerprint

Left ventricular assist devices
Chemotherapy
Hodgkin Disease
Heart-Assist Devices
Radiotherapy
Hemodynamics
Drug Therapy
Heart Failure
Positron emission tomography
Right Ventricular Dysfunction
Tricuspid Valve Insufficiency
Tricuspid Valve
Surgery
Tomography
Mediastinum
Repair
Cardiomyopathies
Stabilization
Heart Ventricles
Lymphoma

Keywords

  • Hodgkin's lymphoma
  • VAD
  • continuous-flow
  • oncotherapy

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of hodgkin's lymphoma? not any more. / Netuka, Ivan; Stepankova, Pavla; Urban, Marian; Maly, Jiri; Szarszoi, Ondrej; Dorazilova, Zora; Kotulak, Tomas; Pirk, Jan.

In: ASAIO Journal, Vol. 59, No. 3, 01.05.2013, p. 320-321.

Research output: Contribution to journalArticle

Netuka, I, Stepankova, P, Urban, M, Maly, J, Szarszoi, O, Dorazilova, Z, Kotulak, T & Pirk, J 2013, 'Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of hodgkin's lymphoma? not any more', ASAIO Journal, vol. 59, no. 3, pp. 320-321. https://doi.org/10.1097/MAT.0b013e318289b992
Netuka, Ivan ; Stepankova, Pavla ; Urban, Marian ; Maly, Jiri ; Szarszoi, Ondrej ; Dorazilova, Zora ; Kotulak, Tomas ; Pirk, Jan. / Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of hodgkin's lymphoma? not any more. In: ASAIO Journal. 2013 ; Vol. 59, No. 3. pp. 320-321.
@article{ba56212cb3b74513b631c0b9ae5d184c,
title = "Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of hodgkin's lymphoma? not any more",
abstract = "Hodgkin's lymphoma is a quite frequent diagnosis, particularly in younger patients, which is normally treated effectively with combined chemotherapy and radiotherapy. Cardiomyopathy induced by these treatments is not uncommon and may progress to advanced-stage heart failure. Due to the cardiotoxicity of chemotherapy for Hodgkin's disease, preexisting heart failure precludes usual therapy. We present a novel strategy of hemodynamic stabilization with an implantable left ventricular assist device (LVAD) prior to radical oncotherapy for Hodgkin's lymphoma. A 33-year-old man with a short history of progressive heart failure was hospitalized due to progressive symptoms. An echocardiogram revealed a dilated left ventricle with an ejection fraction of 18{\%}, moderate right ventricular dysfunction, and moderate to severe tricuspid regurgitation. Supradiaphragmatic-stage Hodgkin's lymphoma was also diagnosed. Due to severe cardiac dysfunction, the patient was not a candidate for the usual chemotherapy and radiotherapy prescribed for this diagnosis. After multidisciplinary consultation and consent from the patient, an LVAD was implanted with tricuspid valve repair. Additionally, affected lymph nodes from the ventral upper mediastinum were excised, and pathological analysis confirmed the lymphoma diagnosis. The patient recovered from surgery and the postoperative course was uneventful. With LVAD support and normalized hemodynamics, chemotherapy and radiotherapy for his Hodgkin's lymphoma were completed, and the patient remains in complete remission documented by positron emission tomography/computed tomography and is well one since LVAD implantation.",
keywords = "Hodgkin's lymphoma, VAD, continuous-flow, oncotherapy",
author = "Ivan Netuka and Pavla Stepankova and Marian Urban and Jiri Maly and Ondrej Szarszoi and Zora Dorazilova and Tomas Kotulak and Jan Pirk",
year = "2013",
month = "5",
day = "1",
doi = "10.1097/MAT.0b013e318289b992",
language = "English (US)",
volume = "59",
pages = "320--321",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of hodgkin's lymphoma? not any more

AU - Netuka, Ivan

AU - Stepankova, Pavla

AU - Urban, Marian

AU - Maly, Jiri

AU - Szarszoi, Ondrej

AU - Dorazilova, Zora

AU - Kotulak, Tomas

AU - Pirk, Jan

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Hodgkin's lymphoma is a quite frequent diagnosis, particularly in younger patients, which is normally treated effectively with combined chemotherapy and radiotherapy. Cardiomyopathy induced by these treatments is not uncommon and may progress to advanced-stage heart failure. Due to the cardiotoxicity of chemotherapy for Hodgkin's disease, preexisting heart failure precludes usual therapy. We present a novel strategy of hemodynamic stabilization with an implantable left ventricular assist device (LVAD) prior to radical oncotherapy for Hodgkin's lymphoma. A 33-year-old man with a short history of progressive heart failure was hospitalized due to progressive symptoms. An echocardiogram revealed a dilated left ventricle with an ejection fraction of 18%, moderate right ventricular dysfunction, and moderate to severe tricuspid regurgitation. Supradiaphragmatic-stage Hodgkin's lymphoma was also diagnosed. Due to severe cardiac dysfunction, the patient was not a candidate for the usual chemotherapy and radiotherapy prescribed for this diagnosis. After multidisciplinary consultation and consent from the patient, an LVAD was implanted with tricuspid valve repair. Additionally, affected lymph nodes from the ventral upper mediastinum were excised, and pathological analysis confirmed the lymphoma diagnosis. The patient recovered from surgery and the postoperative course was uneventful. With LVAD support and normalized hemodynamics, chemotherapy and radiotherapy for his Hodgkin's lymphoma were completed, and the patient remains in complete remission documented by positron emission tomography/computed tomography and is well one since LVAD implantation.

AB - Hodgkin's lymphoma is a quite frequent diagnosis, particularly in younger patients, which is normally treated effectively with combined chemotherapy and radiotherapy. Cardiomyopathy induced by these treatments is not uncommon and may progress to advanced-stage heart failure. Due to the cardiotoxicity of chemotherapy for Hodgkin's disease, preexisting heart failure precludes usual therapy. We present a novel strategy of hemodynamic stabilization with an implantable left ventricular assist device (LVAD) prior to radical oncotherapy for Hodgkin's lymphoma. A 33-year-old man with a short history of progressive heart failure was hospitalized due to progressive symptoms. An echocardiogram revealed a dilated left ventricle with an ejection fraction of 18%, moderate right ventricular dysfunction, and moderate to severe tricuspid regurgitation. Supradiaphragmatic-stage Hodgkin's lymphoma was also diagnosed. Due to severe cardiac dysfunction, the patient was not a candidate for the usual chemotherapy and radiotherapy prescribed for this diagnosis. After multidisciplinary consultation and consent from the patient, an LVAD was implanted with tricuspid valve repair. Additionally, affected lymph nodes from the ventral upper mediastinum were excised, and pathological analysis confirmed the lymphoma diagnosis. The patient recovered from surgery and the postoperative course was uneventful. With LVAD support and normalized hemodynamics, chemotherapy and radiotherapy for his Hodgkin's lymphoma were completed, and the patient remains in complete remission documented by positron emission tomography/computed tomography and is well one since LVAD implantation.

KW - Hodgkin's lymphoma

KW - VAD

KW - continuous-flow

KW - oncotherapy

UR - http://www.scopus.com/inward/record.url?scp=84877751896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877751896&partnerID=8YFLogxK

U2 - 10.1097/MAT.0b013e318289b992

DO - 10.1097/MAT.0b013e318289b992

M3 - Article

C2 - 23644622

AN - SCOPUS:84877751896

VL - 59

SP - 320

EP - 321

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -